{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "60644eeb9a0fb659c7ddd7066caa7b86",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/NDR takeaways unlocking commercial success thru AK112 combos PT to HK226NDR takeaways unlocking commercial success thru _2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:20:48.163519",
      "extracted_at": "2025-10-26T12:20:48.163531"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 10,
        "successful_pages": 10,
        "date": "2025-08-29",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 5,
          "reduction_ratio": 0.28529782345529564
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "47bfe56743969dd9",
      "text": "China (PRC) | Biotechnology",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fa03f4b34a8410de",
      "text": "NDR takeaways, unlocking commercial success thru AK112 combos, PT to HK$226",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f78a1f5b7bb7c9c4",
      "text": "AK112(Ivonescimab)+Chemo hits final OS in 2L+ EGFRm NSCLC, per mgmt. it was reached only recently due to smaller enrollment size. Thanks to its superior safety profile, AK112 quickly entered global Ph3, while it could be challenging for competitor drugs to replicate the track and gives AK112 a 2-3yr lead. Also we view the recent AK112 combo deals as positive, incl. YL201 (B7H3 ADC) combo by Akeso, RVMD and PFE combo by SMMT.Maintain Buy and raise PT to HK$226.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cdba725c40f251f2",
      "text": "**AK112+Chemo hits final OS in 2L+ EGFRm NSCLC** - Akeso announced its HARMONi-A Ph3 trial (AK112+Chemo vs Chemo in 2L+ EGFRm NSCLC) hits final OS. Though investors expected final OS maturity early in the year, per mgmt. it was reached only recently due to smaller enrollment size of the trial (n=322). We think it shows 1) improved trend after immature OS (HR=0.8, at 52% maturity) in 2024; and 2) potential positive read-across to HARMONi global trial with interm OS miss (HR=0.79, &lt;50% maturity).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "62095cc40a713181",
      "text": "**AK112 remains undisputed leader with compelling safety profile and a 2-3yr lead** - Thanks to its superior safety profile, AK112 quickly entered global Ph3 and become the fastest PD-1/VEGF product. While for other competitor drugs, US FDA is likely to require expanded Ph2 trials to demonstrate safety, potentially giving AK112 a 2-3yr lead. More details in our primer on China biotech out-licensing: Shopping in China's Biotech Supermarket.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "70187ad319040573",
      "text": "**Combo strategy prioritized** - We view the recent combo deals as positive, given both Akeso and SMMT are prioritizing combo strategy, which we believe is more important than Harmoni-2 final OS alone. Per CDE, AK112 combo with YL201 (B7H3 ADC) on late stage solid tumors (incl. NSCLC, SCLC), has registered clinical trials on Aug 4. Separately, SMMT announced in Jun on AK112 combo with RVMD's multi-selective RASI daraxonrasib, G12Di zoldonrasib, and G12Ci elironrasib, with a priority on RAsm NSCLC, PDAC, and CRC, on top of SMMT's combo with PFE's vedotin-based ADCs. In LT, Akeso also has a comprehensive in-house pipeline on bsAb ADCs.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1873c5b976e01297",
      "text": "**Key readouts in 2H25 'for AK112** 1) Global Ph3 HARMONi study to be showcased at Presidential Symposium at Spe wCLC 2025, 2) HARMONi-6 Ph3 at Oct ESMO 2025 - could be first step to challenge global SOC (Keytruda+Chemo) in 1L NSCLC.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "401fe186d9442d9a",
      "text": "**1H25 result recap** - Akeso's 1H25 revenue at Rmb1,412mn (+38% yoy), mostly contributed from product sales, and net loss at Rmb570mn on higher R&D cost. **NRDL updates:** AK104's 2L+ cervical cancer and AK112's 2L+ EGFRm NSCLC were included in 2024 NRDL. We think AK112 will PD-1(+) NSCLC and AK104's 1L cervical cancer will be eligible for 2025 NRDL inclusion. Meanwhile, AK101 (IL-12/IL-23) and AK102 (PCSK9) are covered into the NRDL-C **NRDL-B, offering Akeso flexibility to balance price cut and insurance coverage.**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d1c7d101abf8b4e6",
      "text": "**Estimates and Valuation Revision:** We increased PoS of HARMONi given potential positive read-cross and result in new peak sales of AK112 at US\\(7.1bn (vs. prev.6.5bn). Maintain Buy and raise PT to HK\\)226.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3bca7acec4ed0b3b",
      "text": "FY (Dec)2024A2025E2026E2027ERev. (MM)2,166.02,844.14,799.98,955.8Net Profit(514.5)(620.3)686.22,527.1EPS(0.60)(0.05)1.352.45EV/EBITDANMNMNM37.6x",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "02da3d719bcdc5a9",
      "text": "Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 4-10 of this report. * Jefferies Hong Kong Limited",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5e901df07679818d",
      "text": "TARGET CHANGERATINGBUYPRICEHK$152.20*PRICE TARGET |% TO PTHK$226.00 (HK$150.00)|+48%52W HIGH-LOWHK$179.00 - HK$44.50FLOAT (%) | ADV MM (USD)76.5% | 220.57MARKET CAPHK$138.2B | $17.7BTICKER9926 HK",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "62c3b166963fa39d",
      "text": "*Prior trading day's closing price unless otherwise noted. Price: Intraday",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f60619c2b6e56784",
      "text": "FY (Dec)CHANGE TO JEFeJEF vs CONS20252026 2025REV-21%-15% NA NAEPSNANA NA2025 (RMB)1Half2Half FYEPS--(0.05)PREV",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ee95c58f75927108",
      "text": "2025 (RMB)1Half2HalfFYEPS--(0.05)PREV",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "99f039c66d407690",
      "text": "We rate Akeso a Buy for: 1) promising head- to- head data on AK112 (inhouse- developed novel PD- 1/VEGF bispecific antibody) vs. Keytruda on 1L NSCLC, which could unleash overseas potential; 2) further upside for AK112 from global data readout in 2H25E, with peak sales of up to US\\\\$9bn, based on our estimates; and 3) the company's track record in AK104 (PD- 1/CTLA- 4 bsAb) commercialization, which builds confidence in future product sales ramp- up.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "907ce1c277c69c46",
      "text": "Company continues to push its candidates forward in global clinical trials.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0fc72116c6122967",
      "text": "Key assets are approved and commercialized globally.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "17065caaac56715d",
      "text": "PT of HK\\\\$226 based on DCF valuation.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7c5f87fe72b83794",
      "text": "Meaningful partnership in clinical development and commercialization.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7ff7b3fbdcc18fd5",
      "text": "Earlier launch of pipelines and faster sales ramp- up.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "bbfc46acdb119e06",
      "text": "More pipeline candidates from its internal R&D or through in- licensing/ partnerships/ acquisitions.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "461511d68b7e74cc",
      "text": "Upside PT of HK\\\\$293.8 based on DCF valuation.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "90f132be1a7cff51",
      "text": "Pipeline delay/failure.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "44a55948c56d0c02",
      "text": "Breakup in partnerships.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f029b2227fb34854",
      "text": "Downside PT of HK\\\\$115 based on DCF valuation.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "55e99c0fe986f64e",
      "text": "Top Material Issues: 1) Safety of clinical trials, 2) Product quality and safety, 3) Protection of data and privacy, 4) Protection of intellectual property rights, 5) R&D innovation, 6) Compliance with business ethics, 7) Occupational health and safety, 8) Adaptation to climate change and greenhouse gases management",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ab4a072c40a20857",
      "text": "Company Targets: No targets mentioned",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a64b92f0cf406263",
      "text": "1) What is the company's intellectual property protection strategy under the ESG framework? \n2) What is the strategy in talent retention and development in improving human capital?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a5dc26613bb0c8ca",
      "text": "+ SMMT in discussion with MNC on potential M&A.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3e3bbe9637d8d1d3",
      "text": "+ AK112 final OS readout of H2H data vs. Keytruda 1L NSCLC could drive share price up. - YE2025",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "64eddaa3a9b6f9e6",
      "text": "+ Exploration of AK104 overseas opportunity. - 2025 onwards",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "27b495f2441641e2",
      "text": "Chart 1 - Akeso Income Statement",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "46eab3038186b6cc",
      "text": "Income StatementRMB &#x27;0002021202320242025E2026E2027ENet sales1,108,3054,553,8862,165,9872,844,1494,799,8928,955,790COGS(364,766)(160,881)(331,085)(420,526)(685,695)(1,279,392)Revenue837,6564,526,2532,123,9442,844,1494,799,8928,955,790Gross profit743,5394,393,0051,834,9022,423,6234,114,1977,676,398Selling expenses(552,661)(890,384)(1,001,793)(1,023,894)(1,583,964)(2,955,411)G&amp;amp;A expenses(199,007)(200,094)(203,641)(228,078)(250,886)(275,974)R&amp;amp;D expenses(1,323,098)(1,254,023)(1,187,690)(1,600,000)(1,500,000)(1,500,000)Operating income(1,331,227)2,048,504(558,222)(428,348)779,3472,945,013D&amp;amp;A105,789142,768193,968263,908286,572290,825EBITDA(1,225,438)2,191,272(364,254)(164,440)1,065,9193,235,838Other income135,631194,08391,09591,09591,09591,095Other expenses(206,312)(281,450)(172,087)(172,087)(172,087)(172.087)Other gains / (loss) net1,010(51,358)(200,000)00Finance income21,972119,733206,381176,075195,976195,976Finance costs(43,290)(86,987)(68,260)(86,987)(86,987)(86,987)Pretax income(1,422,216)1,942,525(501,093)(620,252)807,3442,973,010Taxes0(174)00(121,102)(445,952)Effective tax rate0.0%0.0%0.0%0.0%15.0%15.0%Net income(1,422,216)1,942,351(501,093)(620,252)686,2422,527,059Minority Interest253,82385,949(13,422)000Net income to common(1,168,393)2,028,300(514,515)(620,252)686,2422,527,059",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "efce35a29c7f7bd7",
      "text": "Source: Company reports, Jefferies research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b3a61e2f78763d30",
      "text": "AkesobioAkeso is a commercial- stage biotech that offers two first- in- class bispecific antibodies - namely AK104 (PD- 1/CTLA- 4, approved in China) and AK112 (PD- 1/VEGF, approved in China). The promising head- to- head data on AK112 vs. Keytruda on 1L NSCLC, which could unleash overseas potential. Meanwhile, the company's track record in AK104 and AK112 commercialization, which builds confidence in future product sales ramp- up.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3c77f6f18558a507",
      "text": "Our DCF- based valuation for Akeso is HK\\$226. Risks: pipeline failure, competition, partnerships, regulations, commercialization, manufacturing, and drug reimbursement.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4610ce0ba9753cfb",
      "text": "Valuation: Our PT is supported by our PE/PEG- relative and DCF- based valuations. Risks include LOEs, R&D, manufacturing, reimbursement, competition, and M&A.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a358b7d9936a6409",
      "text": "REVOLUTION Medicines IncOur \\(88 price target is based on a DCF valuation model, which assumes a WACC of 10.5%, terminal growth rate of 2%, and \\~165 million shares outstanding, driven by sales of RMC- 6236, RMC- 6291 and RMC- 9805 in PDAC, NSCLC and CRC. We do not include other early- stage programs in our model and leave them as future upside. Risks include clinical, regulatory, manufacturing, commercial, financing, and competition.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "ff0d9646a24c9ef7",
      "text": "We arrive at a \\(44 price target based on a DCF valuation model that assumes a WACC of 12%, a terminal growth rate of 0%, and outstanding shares of 737M, driven by sales of ivonesimab. Risks: Clinical, regulatory and/or commercial failure. Competitive, manufacturing and/or financing risks.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "0c38574a9af42a34",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "faa28c55af5201d9",
      "text": "August 28, 2025 12:13 P.M August 28, 2025 12:13 P.M",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "0a8045b615fb549e",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\) is \\(20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1c5e5c5d5c18c327",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8f775b6cd871f88d",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2a73a9ae2780d287",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6d75d0f94ce2a92b",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "abeb7160f16033a5",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8298cf365b420cb0",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "992e323a0c555ded",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "63b0b732e735f5a2",
      "text": "Akeso Inc. (9926 HK: HK\\$152.20, BUY) Pfizer Inc (PFE: \\$25.07, BUY) REVOLUTION Medicines Inc (RVMD: \\$38.04, BUY) Summit Therapeutics Inc (SMMT: \\$24.81, BUY)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "41b6de5f8dc13e05",
      "text": "Rating and Price Target History for: Summit Therapeutics Inc (SMMT) as of 08-27-2025",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e479087ec28b5ede",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company. Legend:",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "fee1049601778428",
      "text": "I: Initiating Coverage \nD: Dropped Coverage \nB: Buy \nH: Hold \nUP: Underperform",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a17d5b0fee08aecd",
      "text": "Distribution of Ratings",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7e37bfa97e2c86fa",
      "text": "CountPercentCountPercentCountPercentBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "eafdedcc9f0d2c73",
      "text": "Jefries does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2d50eeda5320ed70",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "89e1bd6f8f2380aa",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "dd06c3ad18e9421f",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "f8009335fee537f5",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "73b5a4502a91d08f",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fba2a5091eb59566",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bd864df17184d049",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "73000ef3f35aee83",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "cb83099ffc39ac42",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "209b90b54e92b96d",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "9602f404413fd2ca",
      "text": "first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "10b9466bf31d6ea1",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "c8111fa65666580c",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "2b75a3bffeabda58",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a48e354d2157be33",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "b5cdd9e306676866",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "5bfd470d8e2e1d3f",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5d0c80b9042f5778",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5a4c5b76305d0472",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888. JEFFERIES.",
      "page": 9,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "a6462896a7cceab7",
      "name": "Akeso Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1e9a7858f817cec9",
      "name": "Akeso Income",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4bef5611f4e84ce2",
      "name": "Akesobio\n\nAkesobioAkeso",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bfb99b2095cadb06",
      "name": "Akesobio\n\nOur",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5e0adf0048635d01",
      "name": "Biotech Supermarket",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b749a28733936349",
      "name": "Biotechnology\n\nAkesobio",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ba87032713b76abb",
      "name": "Company Targets",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ef7939250a8b4d95",
      "name": "Differ\n\nWe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e736f0c0f1f7561e",
      "name": "Disclosures\n\nJefries",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8f604cf70e528f65",
      "name": "Downside PT",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "98c5e1b74a254ba0",
      "name": "Downside Scenario",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a87247c304f6889b",
      "name": "Dropped Coverage",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8ed3fafbb18d7293",
      "name": "Dubai Financial",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "3411586b906f60f8",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "b1d667db05fe93c4",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "bar",
        "title": "2023年中国新能源汽车销量",
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1月",
              "2月",
              "3月",
              "4月",
              "5月",
              "6月",
              "7月",
              "8月",
              "9月",
              "10月",
              "11月",
              "12月"
            ]
          },
          "y": {
            "unit": "万辆",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "销量",
            "unit": "万辆",
            "values": [
              38.9,
              43.9,
              65.3,
              63.6,
              71.2,
              80.6,
              78,
              84.6,
              90.4,
              95.6,
              102.6,
              111.2
            ]
          }
        ],
        "figure_id": "ac8be7fff95c5803",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 300
            }
          }
        },
        "series": [
          {
            "name": "Historical Data",
            "unit": null,
            "values": [
              {
                "x": "2024",
                "y": 35
              },
              {
                "x": "2024.25",
                "y": 50
              },
              {
                "x": "2024.5",
                "y": 40
              },
              {
                "x": "2024.75",
                "y": 60
              },
              {
                "x": "2025",
                "y": 55
              },
              {
                "x": "2025.25",
                "y": 70
              },
              {
                "x": "2025.5",
                "y": 100
              },
              {
                "x": "2025.75",
                "y": 160
              }
            ]
          },
          {
            "name": "Forecast - Upside",
            "unit": null,
            "values": [
              {
                "x": "2025.75",
                "y": 160
              },
              {
                "x": "+12 mo.",
                "y": 293.8
              }
            ]
          },
          {
            "name": "Forecast - Base",
            "unit": null,
            "values": [
              {
                "x": "2025.75",
                "y": 160
              },
              {
                "x": "+12 mo.",
                "y": 226.0
              }
            ]
          },
          {
            "name": "Forecast - Downside",
            "unit": null,
            "values": [
              {
                "x": "2025.75",
                "y": 160
              },
              {
                "x": "+12 mo.",
                "y": 115.0
              }
            ]
          }
        ],
        "figure_id": "f6648fbc98cd778f",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 2,
        "axes": null,
        "series": [],
        "figure_id": "bdb4ae94836a2c21",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Akeso Inc. (9926 HK) as of 08-27-2025",
        "page": 6,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "HK$",
            "range": {
              "min": 20,
              "max": 180
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "HK$",
            "values": [
              {
                "date": "2022-10",
                "value": 20
              },
              {
                "date": "2023-01",
                "value": 30
              },
              {
                "date": "2023-04",
                "value": 40
              },
              {
                "date": "2023-07",
                "value": 45
              },
              {
                "date": "2023-10",
                "value": 40
              },
              {
                "date": "2024-01",
                "value": 45
              },
              {
                "date": "2024-04",
                "value": 50
              },
              {
                "date": "2024-07",
                "value": 70
              },
              {
                "date": "2024-10",
                "value": 80
              },
              {
                "date": "2025-01",
                "value": 60
              },
              {
                "date": "2025-04",
                "value": 80
              },
              {
                "date": "2025-07",
                "value": 170
              }
            ]
          },
          {
            "name": "Buy Target",
            "unit": "HK$",
            "values": [
              {
                "date": "2024-05-24",
                "value": 38.0
              },
              {
                "date": "2024-05-31",
                "value": 47.0
              },
              {
                "date": "2024-09-02",
                "value": 58.0
              },
              {
                "date": "2024-10-22",
                "value": 102.0
              },
              {
                "date": "2025-04-28",
                "value": 150.0
              }
            ]
          }
        ],
        "figure_id": "1722df1bd1217c9a",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 20,
              "max": 60
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": null,
            "values": [
              {
                "date": "Oct 22",
                "value": 40
              },
              {
                "date": "Jan 23",
                "value": 55
              },
              {
                "date": "Apr 23",
                "value": 40
              },
              {
                "date": "Jul 23",
                "value": 30
              },
              {
                "date": "Oct 23",
                "value": 25
              },
              {
                "date": "Jan 24",
                "value": 30
              },
              {
                "date": "Apr 24",
                "value": 30
              },
              {
                "date": "Jul 24",
                "value": 30
              },
              {
                "date": "Oct 24",
                "value": 28
              },
              {
                "date": "Jan 25",
                "value": 25
              },
              {
                "date": "Apr 25",
                "value": 23
              },
              {
                "date": "Jul 25",
                "value": 26
              }
            ]
          }
        ],
        "figure_id": "9255da22ad8d5565",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for REVOLUTION Medicines Inc (RVMD) as of 07-27-2025",
        "page": 6,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "USD",
            "range": {
              "min": 10,
              "max": 70
            }
          }
        },
        "series": [
          {
            "name": "Stock Price",
            "unit": "USD",
            "values": [
              {
                "date": "Oct 22",
                "value": 18
              },
              {
                "date": "Nov 22",
                "value": 20
              },
              {
                "date": "Dec 22",
                "value": 22
              },
              {
                "date": "Jan 23",
                "value": 25
              },
              {
                "date": "Feb 23",
                "value": 28
              },
              {
                "date": "Mar 23",
                "value": 25
              },
              {
                "date": "Apr 23",
                "value": 28
              },
              {
                "date": "May 23",
                "value": 30
              },
              {
                "date": "Jun 23",
                "value": 32
              },
              {
                "date": "Jul 23",
                "value": 35
              },
              {
                "date": "Aug 23",
                "value": 30
              },
              {
                "date": "Sep 23",
                "value": 25
              },
              {
                "date": "Oct 23",
                "value": 18
              },
              {
                "date": "Nov 23",
                "value": 20
              },
              {
                "date": "Dec 23",
                "value": 25
              },
              {
                "date": "Jan 24",
                "value": 30
              },
              {
                "date": "Feb 24",
                "value": 35
              },
              {
                "date": "Mar 24",
                "value": 40
              },
              {
                "date": "Apr 24",
                "value": 45
              },
              {
                "date": "May 24",
                "value": 48
              },
              {
                "date": "Jun 24",
                "value": 50
              },
              {
                "date": "Jul 24",
                "value": 52
              },
              {
                "date": "Aug 24",
                "value": 55
              },
              {
                "date": "Sep 24",
                "value": 58
              },
              {
                "date": "Oct 24",
                "value": 60
              },
              {
                "date": "Nov 24",
                "value": 62
              },
              {
                "date": "Dec 24",
                "value": 55
              },
              {
                "date": "Jan 25",
                "value": 48
              },
              {
                "date": "Feb 25",
                "value": 45
              },
              {
                "date": "Mar 25",
                "value": 40
              },
              {
                "date": "Apr 25",
                "value": 35
              },
              {
                "date": "May 25",
                "value": 38
              },
              {
                "date": "Jun 25",
                "value": 35
              },
              {
                "date": "Jul 25",
                "value": 38
              }
            ]
          },
          {
            "name": "Price Target 07/08/2024",
            "unit": "USD",
            "values": [
              {
                "date": "07/08/2024",
                "value": 63
              }
            ]
          },
          {
            "name": "Price Target 07/15/2024",
            "unit": "USD",
            "values": [
              {
                "date": "07/15/2024",
                "value": 73
              }
            ]
          },
          {
            "name": "Price Target 11/06/2024",
            "unit": "USD",
            "values": [
              {
                "date": "11/06/2024",
                "value": 86
              }
            ]
          },
          {
            "name": "Price Target 04/28/2025",
            "unit": "USD",
            "values": [
              {
                "date": "04/28/2025",
                "value": 88
              }
            ]
          }
        ],
        "figure_id": "aebaf14b7c00cc41",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for. Summit Therapeutics Inc (SMMT) as of 08-27-2025",
        "page": 7,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "USD",
            "range": {
              "min": 0,
              "max": 40
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "USD",
            "values": [
              {
                "date": "Oct 22",
                "value": 1.0
              },
              {
                "date": "Jan 23",
                "value": 5.0
              },
              {
                "date": "Apr 23",
                "value": 2.0
              },
              {
                "date": "Jul 23",
                "value": 2.5
              },
              {
                "date": "Oct 23",
                "value": 3.0
              },
              {
                "date": "Jan 24",
                "value": 4.0
              },
              {
                "date": "Apr 24",
                "value": 5.0
              },
              {
                "date": "Jul 24",
                "value": 10.0
              },
              {
                "date": "Oct 24",
                "value": 32.0
              },
              {
                "date": "Jan 25",
                "value": 20.0
              },
              {
                "date": "Apr 25",
                "value": 38.0
              },
              {
                "date": "Jul 25",
                "value": 28.0
              }
            ]
          },
          {
            "name": "Price Target 1",
            "unit": "USD",
            "values": [
              {
                "date": "12/06/2024",
                "value": 31.0
              }
            ]
          },
          {
            "name": "Price Target 2",
            "unit": "USD",
            "values": [
              {
                "date": "04/25/2025",
                "value": 44.0
              }
            ]
          }
        ],
        "figure_id": "8c8728456ef438f2",
        "provenance": {
          "page": 7
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "a97dd1455ce6f869",
        "value": 0.52,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "llment size of the trial (n=322). We think it shows 1) improved trend after immature OS (HR=0.8, at 52% maturity) in 2024; and 2) potential positive read-across to HARMONi global trial with interm OS ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4a9fbeac1cb2f3c6",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "24; and 2) potential positive read-across to HARMONi global trial with interm OS miss (HR=0.79, &lt;50% maturity). **AK112 remains undisputed leader with compelling safety profile and a 2-3yr lead** -",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ba7505392d717838",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "NSCLC. ![Figure 0-2](images/0_2.jpg) **1H25 result recap** - Akeso's 1H25 revenue at Rmb1,412mn (+38% yoy), mostly contributed from product sales, and net loss at Rmb570mn on higher R&D cost. **NRDL u",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4c21b50a805d945f",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>PRICE</td><td>HK$152.20*</td></tr><tr><td>PRICE TARGET |% TO PT</td><td>HK$226.00 (HK$150.00)<br>|+48%</td></tr><tr><td>52W HIGH-LOW</td><td>HK$179.00 - HK$44.50</td></tr><tr><td>FLOAT (%) | ADV MM ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "29cba66ad21d7b54",
        "value": 0.765,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>52W HIGH-LOW</td><td>HK$179.00 - HK$44.50</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>76.5% | 220.57</td></tr><tr><td>MARKET CAP</td><td>HK$138.2B | $17.7B</td></tr><tr><td>TICKER</td><t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4751ac6884696ccb",
        "value": -0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e</td><td>JEF vs CONS</td></tr><tr><td></td><td>2025</td><td>2026 2025</td></tr><tr><td>REV</td><td>-21%</td><td>-15% NA NA</td></tr><tr><td>EPS</td><td>NA</td><td>NA NA</td></tr><tr><td></td><td></td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "d5fc9c6d3e45a0f6",
        "value": -0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "vs CONS</td></tr><tr><td></td><td>2025</td><td>2026 2025</td></tr><tr><td>REV</td><td>-21%</td><td>-15% NA NA</td></tr><tr><td>EPS</td><td>NA</td><td>NA NA</td></tr><tr><td></td><td></td><td></td></tr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "301ee2af50cbec04",
        "value": 226.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "Figure 0-0](images/0_0.jpg) NDR takeaways, unlocking commercial success thru AK112 combos, PT to HK$226 AK112(Ivonescimab)+Chemo hits final OS in 2L+ EGFRm NSCLC, per mgmt. it was reached only recentl",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a05deebc326f1e41",
        "value": 226.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "e, incl. YL201 (B7H3 ADC) combo by Akeso, RVMD and PFE combo by SMMT.Maintain Buy and raise PT to HK$226. **AK112+Chemo hits final OS in 2L+ EGFRm NSCLC** - Akeso announced its HARMONi-A Ph3 trial (AK",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "d265070c1586c326",
        "value": 152.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td colspan=\"2\">TARGET CHANGE</td></tr><tr><td>RATING</td><td>BUY</td></tr><tr><td>PRICE</td><td>HK$152.20*</td></tr><tr><td>PRICE TARGET |% TO PT</td><td>HK$226.00 (HK$150.00)<br>|+48%</td></tr><tr>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a41aa94742fab8a9",
        "value": 226.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>BUY</td></tr><tr><td>PRICE</td><td>HK$152.20*</td></tr><tr><td>PRICE TARGET |% TO PT</td><td>HK$226.00 (HK$150.00)<br>|+48%</td></tr><tr><td>52W HIGH-LOW</td><td>HK$179.00 - HK$44.50</td></tr><tr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ec8e67aebf815fb2",
        "value": 150.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d></tr><tr><td>PRICE</td><td>HK$152.20*</td></tr><tr><td>PRICE TARGET |% TO PT</td><td>HK$226.00 (HK$150.00)<br>|+48%</td></tr><tr><td>52W HIGH-LOW</td><td>HK$179.00 - HK$44.50</td></tr><tr><td>FLOAT ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0eb18aa56715f694",
        "value": 179.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "RICE TARGET |% TO PT</td><td>HK$226.00 (HK$150.00)<br>|+48%</td></tr><tr><td>52W HIGH-LOW</td><td>HK$179.00 - HK$44.50</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>76.5% | 220.57</td></tr><tr><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "75eb3e7b3b1ab968",
        "value": 44.5,
        "unit": "$",
        "metric_type": "currency",
        "context": "|% TO PT</td><td>HK$226.00 (HK$150.00)<br>|+48%</td></tr><tr><td>52W HIGH-LOW</td><td>HK$179.00 - HK$44.50</td></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>76.5% | 220.57</td></tr><tr><td>MARKET CAP<",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "01d4452866a79955",
        "value": 138200000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>FLOAT (%) | ADV MM (USD)</td><td>76.5% | 220.57</td></tr><tr><td>MARKET CAP</td><td>HK$138.2B | $17.7B</td></tr><tr><td>TICKER</td><td>9926 HK</td></tr></table> *Prior trading day's clos",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "16aa6f6c497d0757",
        "value": 17700000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>FLOAT (%) | ADV MM (USD)</td><td>76.5% | 220.57</td></tr><tr><td>MARKET CAP</td><td>HK$138.2B | $17.7B</td></tr><tr><td>TICKER</td><td>9926 HK</td></tr></table> *Prior trading day's closing price ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c94511ecdf58a166",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> ## Base Case, HK\\\\$226, +48% Company continues to push its candidates forward in global clinical trials. Key assets are approv",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "cb8d900e7173f957",
        "value": 0.93,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d commercialized globally. PT of HK\\\\$226 based on DCF valuation. ## Upside Scenario, HK\\\\$293.8, +93% Meaningful partnership in clinical development and commercialization. Earlier launch of pipelines",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "1a6d053fcf7dde7c",
        "value": -0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ps/ acquisitions. Upside PT of HK\\\\$293.8 based on DCF valuation. ## Downside Scenario, HK\\\\$115, -24% Pipeline delay/failure. Breakup in partnerships. Downside PT of HK\\\\$115 based on DCF valuation.",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "cac6d2b9c7402e81",
        "value": 9.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ential; 2) further upside for AK112 from global data readout in 2H25E, with peak sales of up to US\\\\$9bn, based on our estimates; and 3) the company's track record in AK104 (PD- 1/CTLA- 4 bsAb) commer",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "1755b2dfcb032930",
        "value": 226.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "p. ![Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> ## Base Case, HK\\\\$226, +48% Company continues to push its candidates forward in global clinical trials. Key assets are",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a6ebd190587bdbcd",
        "value": 226.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "forward in global clinical trials. Key assets are approved and commercialized globally. PT of HK\\\\$226 based on DCF valuation. ## Upside Scenario, HK\\\\$293.8, +93% Meaningful partnership in clinical d",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "afdfd5dd4a4bdae0",
        "value": 293.8,
        "unit": "$",
        "metric_type": "currency",
        "context": "roved and commercialized globally. PT of HK\\\\$226 based on DCF valuation. ## Upside Scenario, HK\\\\$293.8, +93% Meaningful partnership in clinical development and commercialization. Earlier launch of p",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "b567d32b21138de5",
        "value": 293.8,
        "unit": "$",
        "metric_type": "currency",
        "context": "dates from its internal R&D or through in- licensing/ partnerships/ acquisitions. Upside PT of HK\\\\$293.8 based on DCF valuation. ## Downside Scenario, HK\\\\$115, -24% Pipeline delay/failure. Breakup i",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "45eca9106600ca12",
        "value": 115.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "nerships/ acquisitions. Upside PT of HK\\\\$293.8 based on DCF valuation. ## Downside Scenario, HK\\\\$115, -24% Pipeline delay/failure. Breakup in partnerships. Downside PT of HK\\\\$115 based on DCF valu",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "edf8dd363f092246",
        "value": 115.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ide Scenario, HK\\\\$115, -24% Pipeline delay/failure. Breakup in partnerships. Downside PT of HK\\\\$115 based on DCF valuation. ## Sustainability Matters Top Material Issues: 1) Safety of clinical trial",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "ac0534c9d15f9914",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0</td><td>0</td><td>(121,102)</td><td>(445,952)</td></tr><tr><td>Effective tax rate</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Net income<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cce3743db47e5cf1",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>0</td><td>(121,102)</td><td>(445,952)</td></tr><tr><td>Effective tax rate</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Net income</td><td>(1,42",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cec953a72b4b8951",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>(121,102)</td><td>(445,952)</td></tr><tr><td>Effective tax rate</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Net income</td><td>(1,422,216)</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4db11e44d39f2429",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>(445,952)</td></tr><tr><td>Effective tax rate</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Net income</td><td>(1,422,216)</td><td>1,942,351</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2fc405a00863429f",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "52)</td></tr><tr><td>Effective tax rate</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Net income</td><td>(1,422,216)</td><td>1,942,351</td><td>(501,0",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b5a03a78f2d09f68",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>Effective tax rate</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>0.0%</td><td>15.0%</td><td>15.0%</td></tr><tr><td>Net income</td><td>(1,422,216)</td><td>1,942,351</td><td>(501,093)</td><td>(6",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f818c6659ac191c7",
        "value": 0.105,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "UTION Medicines IncOur \\(88 price target is based on a DCF valuation model, which assumes a WACC of 10.5%, terminal growth rate of 2%, and \\~165 million shares outstanding, driven by sales of RMC- 623",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "09d061f725dc2a33",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ce target is based on a DCF valuation model, which assumes a WACC of 10.5%, terminal growth rate of 2%, and \\~165 million shares outstanding, driven by sales of RMC- 6236, RMC- 6291 and RMC- 9805 in P",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a6f2d2cf8c7ee389",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "peutics Inc We arrive at a \\(44 price target based on a DCF valuation model that assumes a WACC of 12%, a terminal growth rate of 0%, and outstanding shares of 737M, driven by sales of ivonesimab. Ris",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4d0e0ae7ea77e38f",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4 price target based on a DCF valuation model that assumes a WACC of 12%, a terminal growth rate of 0%, and outstanding shares of 737M, driven by sales of ivonesimab. Risks: Clinical, regulatory and/o",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f0da3e4f3a94c7f6",
        "value": 226.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "sales ramp- up. ## Company Valuation/Risks ## Akesobio Our DCF- based valuation for Akeso is HK\\$226. Risks: pipeline failure, competition, partnerships, regulations, commercialization, manufacturing,",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "84a5bed8b16b53bd",
        "value": 152.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "tyle such as growth or value. ## Other Companies Mentioned in This Report Akeso Inc. (9926 HK: HK\\$152.20, BUY) Pfizer Inc (PFE: \\$25.07, BUY) REVOLUTION Medicines Inc (RVMD: \\$38.04, BUY) Summit Ther",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "6acb7908fa51e375",
        "value": 25.07,
        "unit": "$",
        "metric_type": "currency",
        "context": "# Other Companies Mentioned in This Report Akeso Inc. (9926 HK: HK\\$152.20, BUY) Pfizer Inc (PFE: \\$25.07, BUY) REVOLUTION Medicines Inc (RVMD: \\$38.04, BUY) Summit Therapeutics Inc (SMMT: \\$24.81, BU",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a5dc6a58ccc7be4d",
        "value": 38.04,
        "unit": "$",
        "metric_type": "currency",
        "context": "eso Inc. (9926 HK: HK\\$152.20, BUY) Pfizer Inc (PFE: \\$25.07, BUY) REVOLUTION Medicines Inc (RVMD: \\$38.04, BUY) Summit Therapeutics Inc (SMMT: \\$24.81, BUY)<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8e6fbbdeb302ec1e",
        "value": 24.81,
        "unit": "$",
        "metric_type": "currency",
        "context": "c (PFE: \\$25.07, BUY) REVOLUTION Medicines Inc (RVMD: \\$38.04, BUY) Summit Therapeutics Inc (SMMT: \\$24.81, BUY)<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bf47c7245ed2cc9a",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td><td></td></tr><tr><td>HOLD</td><td>1",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "857323d5b9350f61",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td><td></td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "f016db8ff2104be8",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td><td></td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>2",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "adf7f95e35e52aed",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>367</td><td>17.38%</td><td>117</td><td>5.54%</td><td></td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0d640982267854a0",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>117</td><td>5.54%</td><td></td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7a87c8a4ba29fcd5",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7336e296b2485fda",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5</td><td>8.67%</td><td>22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td><td></td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6a0cd4d89a9a33a2",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "22</td><td>1.82%</td><td></td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td><td></td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6e1828f529d7af55",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td><td></td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 6
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 9,
      "tables_count": 0,
      "numerical_data_count": 50,
      "passages_count": 77,
      "entities_count": 20
    }
  }
}